Interpretation of the 2021 Asia-Pacific Vitreo-Retina Society Expert Consensus on the Treat-and-Extend Protocol for nAMD

Authors: Sun Junran, Sun Xiaodong
  

Sun Junran, Sun Xiaodong. Interpretation of the 2021 Asia-Pacific Vitreo-Retina Society Expert Consensus on the Treat-and-Extend Protocol for nAMD[J]. Chin J Exp Ophthalmol, 2025, 43(1):9-17. DOI: 10.3760/cma.j.cn115989-20240818-00234.

ABSTRACT                 [Download PDF] [Read Full Text

The treat-and-extend (T&E) protocol for treating neovascular age-related macular degeneration (nAMD) is one of the commonly used anti-vascular endothelial growth factor (VEGF) treatment strategies in clinical practice.It effectively improves vision while extending treatment intervals and reducing the number of clinic visits.In the Asia-Pacific region, where medical resources are limited and patient compliance is often poor, the T&E protocol offers unique advantages.However, there are currently no guidelines on the T&E protocol in this region, and its clinical use lacks standardized treatment pathways.In 2021, the Asia-Pacific Vitreo-Retina Society (APVRS) expert panel reviewed and summarized clinical research on the anti-VEGF T&E protocol, combining this with clinical practice to develop a set of consensus recommendations for using the T&E protocol to treat nAMD in the Asia-Pacific region.This article reviews and interprets the latest T&E treatment protocol proposed by the APVRS expert panel to guide clinicians in standardized treatment.

Wet macular degeneration;Angiogenesis inhibitors;Treat-and-extend regimen;Asia-Pacific Vitreo-Retina Society;Interpretation of expert consensus

Authors Info & Affiliations 

Sun Junran
Department of Ophthalmology, Shanghai General Hospital, Shanghai 200080, China
Sun Xiaodong
Department of Ophthalmology, Shanghai General Hospital, Shanghai 200080, China
(Read 3 times, 1 visits today)